The National Institutes of Health proposed new conflict-of-interest rules today that will do nothing to limit financial ties between government-funded researchers and private industry and leaves university administrators in charge of policing the arrangements. The 112-page proposed rule, which was years in the making, did lower the threshold for reporting conflicts of interest to $5,000 from […]
Last summer, documents uncovered in a lawsuit against Wyeth-Ayerst, the manufacturer of hormone replacement therapy, revealed that 26 journal articles touting HRT for post-menopausal women written after serious risks had become known were ghostwritten by Wyeth consultants. A new study of the five most prolific authors of HRT-related editorials, clinical practice guidelines and reviews over […]
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
The Cleveland Clinic has admitted that its former staff physician and inventor, Dr. Jay Yadav, did not run afoul of the health system’s conflicts of interest policy as it had claimed in 2006 while declining to renew Yadav’s employment contract. Yadav, an interventional cardiologist, entrepreneur and head of the Clinic’s innovations unit at the time […]
So a clinical trial designed to study safety shows that a treatment produces significantly more death and survivable complications is presented to a group of people with several hundred patients. In the group with no treatment there was a 25% complication rate and with the group getting treatment there was a 75% complication rate. However, […]
A recent story in the Wall Street Journal highlights the fact that, on battlefields today, urgency, acuity and need are still drivers for surgical innovation. Here’s the story: On Battlefields, Survival Odds Rise Every war brings medical innovations, as horrific injuries force surgeons to come up with new ways to save lives. During the Civil […]
Merrill Goozner examines recent ethical quandaries in both health care and journalism -- and contrasts those situations with the public perception of the medical and journalistic professions.
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
Speaking to a group of fellow chief executives, Pfizer's CEO warned that the American public is mad as hell and they're not going to take it any more, so to speak, when it comes to corporate malfeasance.
Researchers at Case Western Reserve University and the Cleveland Clinic have won two grants -- together worth nearly $2 million -- to study how underserved and minority communities view genomics research, and the bioethics of using deep brain stimulation to help Parkinson's patients.
There's a greater consideration for research institutions to outsource their ethical review boards. But Nancy Walton says the arms-length approach can increase costs and create a board that's out of touch with the community their overseeing.
The inspector general of the U.S. Department of Health and Human Services is investigating a conflict-of-interest allegation involving the nation's top drug regulator, Janet Woodcock, according to the U.S. Food and Drug Administration. On Tuesday, the FDA's top medical-device regulator, Daniel Schultz, said he would resign "by mutual agreement" with FDA Commissioner Margaret Hamburg.
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.
Merrill Goozner sees two possible motives for the data-faking controversy at the University of Alabama at Birmingham: professional greed and personal greed. He reviews the evidence.
Kendle stated that its new operations in Kuala Lumpur, Manila and Bagnkok will expand its competitive edge in the region. Kendle, based in Cincinnati, has operated in Asia since 1998 and already has a total of eight offices in China, India, Singapore and Australia.
A new study from the University of Michigan found that results from random cancer trials in top medical journals were more likely to favor an industry when it funded the study. But University Hospitals Vice President Phil Cola said the key to managing bias is banning sources of funding, but getting institutions to do a better job of managing risks.
The Institute of Medicine said in a report that doctors should stop taking much of the money, gifts and free drug samples they routinely accept from drug and device companies. It was a more stinging report than a similar one issued last year by the Association of American Medical Colleges, which prompted policy changes among medical professionals.
It appears that not only doctors and medical students are hearing the siren song of the pharmaceutical industry. So are medical researchers.